Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) shares reached a new 52-week low on Monday after JPMorgan Chase & Co. lowered their price target on the stock from $1,100.00 to ...

We recently published a list of 7 Most Profitable Biotech Stocks To Buy Right Now. In this article, we are going to take a ...

Intellia has collaborated with Regeneron Pharmaceuticals REGN for the development of nex-z. Nex-z is part of the company’s co-development and co-promotion agreement with Regeneron. While NTLA is ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price objective dropped by analysts at JPMorgan Chase & Co. from $1,100.00 to $1,000.00 in a report released on Monday ...

We recently published a list of 11 Blue Chip Stocks to Invest in at 52-Week Lows. In this article, we are going to take a ...

Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-five analysts that are covering the ...

Regeneron: This biotechnology company’s portfolio includes Eylea (for several eye diseases), its key growth driver. Eylea is approved in the United States, the EU, Japan and other countries for ...

In this article, we are going to take a look at where Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) stands against other blue chip stocks to invest in at 52-week lows. For the first time since ...

Pharmaceutical (TADAWUL:2070) stocks saw brief relief Thursday after U.S. President Donald Trump left drug products off the list of newly announced tariffs. However, industry leaders and analysts ...

TARRYTOWN, N.Y., March 25, 2025 (GLOBE NEWSWIRE) -- Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) today announced that it will report its first quarter 2025 financial and operating results on ...

Q4 2024 Earnings Call Transcript March 31, 2025 Operator: Ladies and gentlemen, thank you for standing by. Welcome to the ...